ReviewAIDS patient care and STDs2008
Hepatitis C protease and polymerase inhibitors in development.
Review in AIDS patient care and STDs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 50 citations in OpenAlex.
- Prodrug strategies in developing antiviral nucleoside analogs.RSC medicinal chemistry · 2026Review
- Fungal Proteases as Emerging Biocatalysts to Meet the Current Challenges and Recent Developments in Biomedical Therapies: An Updated Review.Journal of fungi (Basel, Switzerland) · 2022Review
- Green Technique-Solvent Free Microwave Synthesis and Antimicrobial Evaluation of New Thiopyridine Arabinosides.Molecules (Basel, Switzerland) · 2016Article
- Article
- Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.ACS chemical biology · 2012Article
- New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Journal of Zhejiang University. Science. B · 2012Review
- Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.AIDS patient care and STDs · 2011Article
- Current treatment of choice for chronic hepatitis C infection.Infection and drug resistance · 2011Article
- A perspective on modelling hepatitis C virus infection.Journal of viral hepatitis · 2010Review
- Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model.Antiviral research · 2010Article
- Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2010Review
- Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.Critical reviews in immunology · 2010Review
- Synthesis, antiviral activity, and stability of nucleoside analogs containing tricyclic bases.European journal of medicinal chemistry · 2009Article
- Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.AIDS patient care and STDs · 2009Article
- Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry.Chemical reviews · 2009Review
- Molecular targets for flavivirus drug discovery.Antiviral research · 2009Review
- Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C infection (HCV) remains a global problem and the current anti-HCV therapies available in the clinic have sustained virologic response rates (SVR) of only about 50%, especially in HCV genotype 1-infected subjects. The SVR is even lower in HIV-HCV co-infected patients, estimated at only about 30-40%. However, exciting new research is under way to find new anti-HCV therapies. Presently, efforts to develop new anti-HCV agents for HCV-infected persons who fail pegylated interferon and ribavirin-based therapies have focused on inhibitors of key HCV enzymes such as the HCV NS3 protease and the NS5B polymerase. There are two protease inhibitors, telaprevir (VX-950, Vertex) and boceprevir (SCH 503034, Schering-Plough); and three polymerase inhibitors, valopicitabine (NM283, Idenix), R1626 (Roche), and HCV-796 (Viropharma) that have advanced to late-stage clinical trials. Of these aforementioned agents, telaprevir is the most advanced in clinical development. Early trial results on efficacy, safety, and HCV drug-resistance profiles of these novel agents will be discussed in this review paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.